Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2611 to 2625 of 9044 results

  1. Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]

    In development Reference number: GID-TA11100 Expected publication date:  13 May 2027

    Technology appraisal guidance
    In development

  2. Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

    In development Reference number: GID-TA10575 Expected publication date:  05 August 2026

    Technology appraisal guidance
    In development

  3. Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]

    In development Reference number: GID-TA11774 Expected publication date:  30 September 2026

    Technology appraisal guidance
    In development

  4. Osteoporosis

    In development Reference number: GID-QS10188 Expected publication date: TBC

    Quality standard
    In development

  5. Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]

    In development Reference number: GID-HST10062 Expected publication date:  17 March 2027

    Highly specialised technologies guidance
    In development

  6. Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer [ID6399]

    Awaiting development Reference number: GID-TA11499 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Anitocabtagene autoleucel for treating relapsed or refractory multiple myeloma ID6549

    In development Reference number: GID-TA11722 Expected publication date:  20 May 2027

    Technology appraisal guidance
    In development

  8. Acalabrutinib with venetoclax for untreated chronic lymphocytic leukaemia [ID6232]

    In development Reference number: GID-TA11230 Expected publication date:  19 August 2026

    Technology appraisal guidance
    In development

  9. Gender Incongruence Services for Children and Young People

    In development Reference number: GID-QS10193 Expected publication date:  18 February 2027

    Quality standard
    In development

  10. Gender incongruence in children and young people

    Topic prioritisation

    NICE guideline
    Topic prioritisation

  11. Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain

    In development Reference number: GID-HTG10168 Expected publication date: TBC

    HealthTech guidance
    In development

  12. Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 30 June 2026.

    Technology appraisal guidance
    In consultation

  13. Software with artificial intelligence (AI)-derived algorithms to help interpret electroencephalograms (EEGs) for suspected epilepsy: early-use assessment: draft guidance

    We are listening to your views on this HealthTech guidance. Comments close 30 June 2026.

    In consultation

  14. Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]

    In development Reference number: GID-TA11651 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Brentuximab vedotin in combination for untreated advanced classical Hodgkin lymphoma [ID6437]

    In development Reference number: GID-TA11516 Expected publication date:  06 May 2027

    Technology appraisal guidance
    In development